Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes

Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16.

Authors

Janghee Woo^{1

2}, Nicholas P Howard², Barry E Storer¹, Min Fang¹, Cecilia C Yeung¹, Bart L Scott¹, H Joachim Deeg³

Affiliations

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA.
² Department of Genome Sciences, University of Washington, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA [email protected].

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / therapeutic use*
Biomarkers, Tumor
Bone Marrow / pathology
Bone Marrow Cells / metabolism*
Bone Marrow Cells / pathology
DNA Mutational Analysis
Hematopoietic Stem Cell Transplantation / methods
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Mutation*
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / genetics*
Myelodysplastic Syndromes / mortality
Myelodysplastic Syndromes / pathology
Postoperative Care
Prognosis

Substances

Antimetabolites, Antineoplastic
Biomarkers, Tumor
Azacitidine

Grants and funding